HIV / AIDS in the News

Reformulation of HIV prevention drug lenacapavir makes it last for a year - Medical Xpress

 

Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH - AJMC.com Managed Markets Network

 

Cabotegravir Combined With Broadly Neutralizing Antibodies Maintains Undetectable HIV - Contagionlive.com

 

ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV - Business Wire

 

Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48 - Business Wire

 

Breakthrough: Merck's Novel HIV Two-Drug Combo Achieves 95% Viral Suppression in Phase 3 - StockTitan

 

GSK posts data on HIV assets vying for roles in 6-month combo - Fierce Biotech

 

#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks longer-acting HIV treatment - Endpoints News

 

DTG/3TC, Fostemsavir Effective as ART for Patients With HIV - AJMC.com Managed Markets Network

 

Lenacapavir plus broadly neutralising antibodies could be twice-yearly HIV treatment - aidsmap

 

People with HIV in Malawi Face Greater Risk for Dementia - NYU News

 

Gilead Presents Encouraging Long-term Data For Biktarvy In People With HIV And HBV Coinfection - Nasdaq

 

Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts - BioSpace

 

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option - BioSpace

 

Bictegravir vs Darunavir in Advanced HIV: Results from the LAPTOP Trial - Contagionlive.com

 

HIV Researchers and Advocates Rally to Save Our Sciences - POZ

 

SAMHSA employees detail an agency in shambles - STAT

 

Gilead Sciences (GILD) Presents New HIV Treatment and Cure Research Data - StreetInsider.com

 

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option - Business Wire

 

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option - Yahoo Finance

 

HIV Rapid Test Kits Market Focused Insights 2025-2030: - GlobeNewswire

 

Ibalizumab shows promise for drug-resistant HIV patients - Investing.com

 

HIV Rapid Test Kits Market Focused Insights 2025-2030: Abbott, Bio-Rad, and bioMerieux Strengthen Market Position Amid Rising Competition - Yahoo Finance

 

Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV - News-Medical.Net

 

Gilead hops straight to Phase III with once-yearly HIV PrEP shot - FirstWord Pharma

 

Gaps in HPV cancer screening and prevention identified for people living with HIV - News-Medical.Net

 

Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals - The Financial Express

 

Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success - Clinical Trials Arena

 

Theratechnologies CROI Presentation Highlights Limitations - GlobeNewswire

 

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI - GlobeNewswire